1
|
Zhao L, Ling L, Lu J, Jiang F, Sun J, Zhang Z, Huang Y, Liu X, Zhu Y, Fu X, Peng S, Yuan W, Zhao R, Zhang Z. Reactive oxygen species‐responsive mitochondria‐targeted liposomal quercetin attenuates retinal ischemia–reperfusion injury via regulating
SIRT1
/
FOXO3A
and p38
MAPK
signaling pathways. Bioeng Transl Med 2022; 8:e10460. [DOI: 10.1002/btm2.10460] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2022] [Revised: 11/15/2022] [Accepted: 11/17/2022] [Indexed: 12/03/2022] Open
Affiliation(s)
- Laien Zhao
- School of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong Yantai University Yantai People's Republic of China
| | - Longbing Ling
- School of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong Yantai University Yantai People's Republic of China
| | - Jing Lu
- School of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong Yantai University Yantai People's Republic of China
| | - Feng Jiang
- Department of Ophthalmology Tianjin Medical University General Hospital Tianjin People's Republic of China
| | - Jianchao Sun
- School of Environment and Material Engineering Yantai University Yantai People's Republic of China
| | - Zhen Zhang
- College of Chemistry and Chemical Engineering Yantai University Yantai People's Republic of China
| | - Yanmei Huang
- School of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong Yantai University Yantai People's Republic of China
| | - Xiaoqian Liu
- School of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong Yantai University Yantai People's Republic of China
| | - Yanjuan Zhu
- School of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong Yantai University Yantai People's Republic of China
| | - Xiaoxuan Fu
- School of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong Yantai University Yantai People's Republic of China
| | - Shengjun Peng
- School of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong Yantai University Yantai People's Republic of China
| | - Wenze Yuan
- School of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong Yantai University Yantai People's Republic of China
| | - Ruikang Zhao
- School of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong Yantai University Yantai People's Republic of China
| | - Zhuhong Zhang
- School of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong Yantai University Yantai People's Republic of China
| |
Collapse
|
2
|
Song Y, Ismail M, Shan Q, Zhao J, Zhu Y, Zhang L, Du Y, Ling L. ROS-mediated liposomal dexamethasone: a new FA-targeted nanoformulation to combat rheumatoid arthritis via inhibiting iRhom2/TNF-α/BAFF pathways. NANOSCALE 2021; 13:20170-20185. [PMID: 34846489 DOI: 10.1039/d1nr05518f] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/26/2023]
Abstract
Rheumatoid arthritis (RA) is an autoimmune inflammatory disorder that has seriously affected human health worldwide and its current management requires more successful therapeutic approaches. The combination of nanomedicines and pathophysiology into one system may provide an alternative strategy for precise RA treatment. In this work, a practical ROS-mediated liposome, abbreviated as Dex@FA-ROS-Lips that comprised synthetic dimeric thioether lipids (di-S-PC) and a surface functionalized with folic acid (FA), was proposed for dexamethasone (Dex) delivery. Incorporation with thioether lipids and a FA segment significantly improved the triggered release and improved the triggered release of cytotoxic Dex as well as the active targeting of RA, altering its overall pharmacokinetics and safety profiles in vivo. As proof, the designed Dex@FA-ROS-Lips demonstrated effective internalization by LPS-activated Raw264.7 macrophages with FA receptor overexpression and released Dex at the inflammatory site due to the ROS-triggered disassembly. Intravenous injection of this Dex@FA-ROS-Lips into adjuvant-induced arthritis (AIA) mice led to its incremental accumulation in inflamed joint tissues and significantly alleviated the cartilage destruction and joint swelling via suppression of proinflammatory cytokines (iRhom2, TNF-α and BAFF), as compared to the effect of commercial free Dex. Importantly, the Dex@FA-ROS-Lips nanoformulation showed better hemocompatibility with less adverse effects on the body weight and immune organ index of AIA mice. The anti-inflammatory mechanism of Dex@FA-ROS-Lips was further studied and it was found that it is possibly associated with the down-regulation of iRhom2 and the activation of the TNF-α/BAFF signaling pathway. Therefore, the integration of nanomedicines and the RA microenvironment using multifunctional Dex@FA-ROS-Lips shall be a novel RA treatment modality with full clinical potential, and based on the enhanced therapeutic effect, the signaling pathway of iRhom2/TNF-α/BAFF reasonably explained the mechanism of Dex@FA-ROS-Lips in anti-RA, which suggested a molecular target for RA therapy and other inflammatory diseases.
Collapse
Affiliation(s)
- Yanqin Song
- Key Laboratory of Molecular Pharmacology and Drug Evaluation (Ministry of Education of China), School of Pharmacy, Yantai University, Yantai 264005, China.
- Yantai Center for Food and Drug Control, Yantai 264005, China
| | - Muhammad Ismail
- Henan-Macquarie University Joint Center for Biomedical Innovation, School of Life Science, Henan University, Kaifeng, Henan 475004, China
| | - Qi Shan
- Key Laboratory of Molecular Pharmacology and Drug Evaluation (Ministry of Education of China), School of Pharmacy, Yantai University, Yantai 264005, China.
| | - Jianing Zhao
- Key Laboratory of Molecular Pharmacology and Drug Evaluation (Ministry of Education of China), School of Pharmacy, Yantai University, Yantai 264005, China.
| | - Yanping Zhu
- Key Laboratory of Molecular Pharmacology and Drug Evaluation (Ministry of Education of China), School of Pharmacy, Yantai University, Yantai 264005, China.
| | - Leiming Zhang
- Key Laboratory of Molecular Pharmacology and Drug Evaluation (Ministry of Education of China), School of Pharmacy, Yantai University, Yantai 264005, China.
| | - Yuan Du
- Key Laboratory of Molecular Pharmacology and Drug Evaluation (Ministry of Education of China), School of Pharmacy, Yantai University, Yantai 264005, China.
| | - Longbing Ling
- Key Laboratory of Molecular Pharmacology and Drug Evaluation (Ministry of Education of China), School of Pharmacy, Yantai University, Yantai 264005, China.
| |
Collapse
|
3
|
Márquez-Cadena MA, Ren J, Ye W, Qian P, Tong R. Asymmetric Total Synthesis Enables Discovery of Antibacterial Activity of Siladenoserinols A and H. Org Lett 2019; 21:9704-9708. [PMID: 31747295 DOI: 10.1021/acs.orglett.9b03857] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Siladenoserinols A and H were found to show moderate inhibitory activity toward p53-Hdm2 interactions. Our total synthesis allowed us to further examine their bioactivities, which revealed that (i) siladenoserinols A and H were not cytotoxic against cancer cell lines and (ii) siladenoserinol A and its desulfamate analogue exhibited significant antibacterial activity against Gram-positive bacteria including MRSA. Our studies demonstrate that siladenoserinols are a promising new class of bactericidal Gram-positive antibiotics without hemolytic activity.
Collapse
Affiliation(s)
| | - Jingyun Ren
- Department of Chemistry , The Hong Kong University of Science and Technology , Hong Kong , China
| | - Wenkang Ye
- Department of Ocean Science, Division of Life Science and Hong Kong Branch of the Southern Marine Science and Engineering Guangdong Laboratory , The Hong Kong University of Science and Technology , Hong Kong , China
| | - Peiyuan Qian
- Department of Ocean Science, Division of Life Science and Hong Kong Branch of the Southern Marine Science and Engineering Guangdong Laboratory , The Hong Kong University of Science and Technology , Hong Kong , China
| | - Rongbiao Tong
- Department of Chemistry , The Hong Kong University of Science and Technology , Hong Kong , China
| |
Collapse
|
4
|
Liu J, Zhou Z, Liu J, Yan J, Fan L, Tang X, Liu J, Chen F, Yang D. Synthesis and Investigation on the Antidiabetic Effect of 3-aryl-1-(5-methylisoxazol-3-ylamino)-1-(4-nitrophenyl) Propan-1-one. LETT DRUG DES DISCOV 2019. [DOI: 10.2174/1570180815666180608101529] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Background:
Diabetes mellitus is the third-largest non-communicable chronic disease
worldwide. There are many effective drugs, but the long-term use of these clinical drugs may cause
various side effects. Therefore, it is urgent to develop new antidiabetic molecules with higher efficacy
and lower toxicity.
Methods:
Fifteen new 3-aryl-1-(5-methylisoxazol-3-ylamino)-1-(4-nitrophenyl)propan-1-one were
synthesized directly through the Mannich reaction of 4-nitroacetophenone, 3-amino-5-
methylisoxazole and aromatic aldehydes catalyzed by concentrated hydrochloric acid. The molecular
structures of the products were fully characterized by 1H NMR, 13C NMR, ESI MS and HRMS.
The peroxisome proliferator-activated receptor (PPAR) response element and α-glucosidase inhibitory
activity of these compounds were evaluated in vitro. Molecular docking, molecular physical
parameters calculation, and molecular toxicity prediction were performed to analyze the structure-
activity relationship and evaluate the druggability of these compounds theoretically.
Results:
All compounds exhibited weak antidiabetic activities, but compound 15 showed promising
as a high performance, dual-target antidiabetic lead compound with peroxisome proliferatoractivated
receptor (PPAR) response element relative agonist activity of 99.55% at 27.2 nmol·mL−1
and α-glucosidase inhibitory activity of 35.21% at 13.6 nmol·mL−1. All compounds obtained may
have no cardiotoxicity, no acute toxicity, no carcinogenic, and within safe range of mutagenic risk.
Conclusion:
This study identified a potential PPAR lead molecule and presented an unusual strategy
for antidiabetic drug development.
Collapse
Affiliation(s)
- Jinyu Liu
- School of Chemistry and Chemical Engineering, Southwest University, Chongqing 400715, China
| | - Zuwen Zhou
- School of Chemistry and Chemical Engineering, Southwest University, Chongqing 400715, China
| | - Jian Liu
- School of Chemistry and Chemical Engineering, Southwest University, Chongqing 400715, China
| | - Jufang Yan
- Drug Screening Center, Chengdu DiAo Pharmaceutical Group Co. Ltd, Chengdu 610041, China
| | - Li Fan
- School of Chemistry and Chemical Engineering, Southwest University, Chongqing 400715, China
| | - Xuemei Tang
- School of Life Science, Southwest University, Chongqing 400715, China
| | - Jie Liu
- School of Chemistry and Chemical Engineering, Southwest University, Chongqing 400715, China
| | - Feifei Chen
- School of Chemistry and Chemical Engineering, Southwest University, Chongqing 400715, China
| | - Dacheng Yang
- School of Chemistry and Chemical Engineering, Southwest University, Chongqing 400715, China
| |
Collapse
|
5
|
Abstract
Understanding and exploiting molecular mechanisms in biology is central to chemical biology. Chemical biology studies of biological macromolecules are now in a perfect continuum with molecular level and nanomolecular level mechanistic studies involving whole organisms. The potential opportunity presented by such studies is the design and creation of genuine precision active pharmaceutical ingredients (APIs; including DNA, siRNA, smaller-molecule bioactives) that demonstrate exceptional levels of disease target specificity and selectivity. This article covers the best of my personal and collaborative academic research work using an organic chemistry and chemical biology approach towards understanding biological molecular recognition processes, work that appears to be leading to the generation of novel precision APIs with genuine potential for the treatments of major chronic diseases that afflict globally.
Collapse
|
6
|
Lund J, Stensrud C, Rajender, Bohov P, Thoresen GH, Berge RK, Wright M, Kamal A, Rustan AC, Miller AD, Skorve J. The molecular structure of thio-ether fatty acids influences PPAR-dependent regulation of lipid metabolism. Bioorg Med Chem 2016; 24:1191-203. [PMID: 26874397 DOI: 10.1016/j.bmc.2016.01.045] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2015] [Revised: 01/19/2016] [Accepted: 01/21/2016] [Indexed: 10/22/2022]
Abstract
Thio-ether fatty acids (THEFAs), including the parent 2-(tetradecylthio)acetic acid (TTA), are modified fatty acids (FAs) that have profound effects on lipid metabolism given that they are blocked for β-oxidation, and able to act as peroxisome proliferator-activated receptor (PPAR) agonists. Therefore, TTA in particular has been tested clinically for its therapeutic potential against metabolic syndrome related disorders. Here, we describe the preparation of THEFAs based on the TTA scaffold with either a double or a triple bond. These are tested in cultured human skeletal muscle cells (myotubes), either as free acid or following esterification as phospholipids, lysophospholipids or monoacylglycerols. Metabolic effects are assessed in terms of cellular bioavailabilities in myotubes, by FA substrate uptake and oxidation studies, and gene regulation studies with selected PPAR-regulated genes. We note that the inclusion of a triple bond promotes THEFA-mediated FA oxidation. Furthermore, esterification of THEFAs as lysophospholipids also promotes FA oxidation effects. Given that the apparent clinical benefits of TTA administration were offset by dose limitation and poor bioavailability, we discuss the possibility that a selection of our latest THEFAs and THEFA-containing lipids might be able to fulfill the therapeutic potential of the parent TTA while minimizing required doses for efficacy, side-effects and adverse reactions.
Collapse
Affiliation(s)
- Jenny Lund
- Department of Pharmaceutical Biosciences, School of Pharmacy, University of Oslo, Norway
| | - Camilla Stensrud
- Department of Pharmaceutical Biosciences, School of Pharmacy, University of Oslo, Norway
| | - Rajender
- Imperial College Genetic Therapies Centre, Department of Chemistry, Flowers Building, Imperial College London, UK; Division of Organic Chemistry, Indian Institute of Chemical Technology, Hyderabad, India
| | - Pavol Bohov
- Department of Clinical Science, University of Bergen, N-5021 Bergen, Norway
| | - G Hege Thoresen
- Department of Pharmaceutical Biosciences, School of Pharmacy, University of Oslo, Norway; Department of Pharmacology, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo and Oslo University Hospital, Norway
| | - Rolf K Berge
- Department of Clinical Science, University of Bergen, N-5021 Bergen, Norway; Department of Heart Disease, Haukeland University Hospital, Norway
| | - Michael Wright
- Imperial College Genetic Therapies Centre, Department of Chemistry, Flowers Building, Imperial College London, UK; Institute of Pharmaceutical Science, Franklin-Wilkins Building, King's College London, UK
| | - Ahmed Kamal
- Division of Organic Chemistry, Indian Institute of Chemical Technology, Hyderabad, India
| | - Arild C Rustan
- Department of Pharmaceutical Biosciences, School of Pharmacy, University of Oslo, Norway
| | - Andrew D Miller
- Division of Organic Chemistry, Indian Institute of Chemical Technology, Hyderabad, India; Institute of Pharmaceutical Science, Franklin-Wilkins Building, King's College London, UK; GlobalAcorn Ltd, London, UK
| | - Jon Skorve
- Department of Clinical Science, University of Bergen, N-5021 Bergen, Norway.
| |
Collapse
|
7
|
Synthesis of novel β-amino ketones containing a p-aminobenzoic acid moiety and evaluation of their antidiabetic activities. Sci China Chem 2013. [DOI: 10.1007/s11426-012-4816-2] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
8
|
Bhurruth-Alcor Y, Rost TH, Jorgensen MR, Rajender, Müller M, Skorve J, Berge RK, Miller AD. Novel phospholipid analogues of pan-PPAR activator tetradecylthioacetic acid are more PPARα selective. Bioorg Med Chem Lett 2010; 20:1252-5. [DOI: 10.1016/j.bmcl.2009.11.115] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2009] [Revised: 11/20/2009] [Accepted: 11/21/2009] [Indexed: 10/20/2022]
|